Cat. No.
MABL-3670
Application
Block, ELISA, EM
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
Eculizumab
From
Recombinant Antibody
Specificity
Binds human C5 centred in the MG7 domain, at an epitope spanning Lys-879 to Arg-885 (Jore et al. 2016) Polymorphisms at Arg-885 correlate with drug resistance. Eculizumab demonstrates no appreciable species cross-reactivity. It is highly species specific. with no appreciable activity against chimpanzee, baboon, rhesus or cynomologous monkey, pig, rabbit, guinea pig, or rat complement
Alternative Names
Complement Component 5; CPAMD4; Complement protein C5; h5G1.1
UniProt
P01031
Immunogen
C5 is activated by C5 converatse into C5a, an anaphylatoxin, and C5b a component of the membrane attack complex.
Application Notes
This antibody inhibits activation of C5. The human Fab version (Ab00296-10.6) of this antibody was used by Jore et al. (2016, PMID: 27018802) to determine the binding site of this antibody to C5.
Antibody First Published
Rother et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. PMID:17989688
Note on publication
Describes development and characterisation of Eculizumab.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
